Multi Protein Nanoparticle Monkeypox Vaccine

https://www.techtransfer.nih.gov/tech/tab-3847?utm_campaign=+57669576&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= In 2022, the World Health Organization declared an outbreak of mpox, causing approximately 30,000 cases of mpox infection within the United States. With mpox posing a current threat to public health, there is a need for additional effective vaccine technologies. NIAID scientists have developed a vaccine approach comprising virus-like nanoparticles coated with modified mpox proteins. This method has elicited a robust immune response and provided protection in preclinical animal studies. The nanoparticle vaccine may have fewer side effects than available vaccines and can be adapted for other poxviruses. Nanoparticle vaccines are also better suited than current vaccines for transport and storage in low resource settings. Read more about this exciting licensing and collaboration opportunity at: https://bit.ly/3rbTOf0 For more information, please contact Benjamin Hurley at 240-669-5092 or benjamin.hurley@nih.gov and reference technology # E-183-2022